Trial reportAlcoholism, clinical and experimental research2012
Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence.
Trial report in Alcoholism, clinical and experimental research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Selective serotonin reuptake inhibitors in the treatment of depression, anxiety, and post-traumatic stress disorder in substance use disorders: a Bayesian meta-analysis.European journal of clinical pharmacology · 2022Pooled it
- Antidepressants for the treatment of people with co-occurring depression and alcohol dependence.The Cochrane database of systematic reviews · 2018Pooled it
- Pharmacotherapy for anxiety and comorbid alcohol use disorders.The Cochrane database of systematic reviews · 2015Pooled it
- Serotonergic gene variation in substance use pharmacotherapy: a systematic review.Pharmacogenomics · 2015Pooled it
- Combining seeking safety with sertraline for PTSD and alcohol use disorders: A randomized controlled trial.Journal of consulting and clinical psychology · 2015Trial
- Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review.Frontiers in pharmacology · 2022Review
- Pharmacogenetics of Addiction Therapy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications.Expert review of precision medicine and drug development · 2020Article
- Mechanisms of Shared Vulnerability to Post-traumatic Stress Disorder and Substance Use Disorders.Frontiers in behavioral neuroscience · 2020Review
- Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice.Alcoholism, clinical and experimental research · 2016Article
- Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.Progress in neuro-psychopharmacology & biological psychiatry · 2016Review
- Serotonergic Systems in the Pathophysiology of Ethanol Dependence: Relevance to Clinical Alcoholism.ACS chemical neuroscience · 2015Review
- Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism.Pharmacology, biochemistry, and behavior · 2014Review
- Neurochemical mechanisms of alcohol withdrawal.Handbook of clinical neurology · 2014Review
- Review
- Polymorphisms of the serotonin transporter and receptor genes: susceptibility to substance abuse.Substance abuse and rehabilitation · 2012Article
- Use of novel technology-based techniques to improve alcohol-related outcomes in clinical trials.Alcohol and alcoholism (Oxford, Oxfordshire)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPharmacotherapy studies in alcohol dependence (AD) are generally of short duration and do not include post-treatment follow-up. We examined the durability of treatment effects in a placebo-controlled trial of sertraline for AD.
methodsAs previously reported, patients received 12 weeks of treatment with sertraline (n = 63) or placebo (n = 71), followed by assessments at 3 and 6 months post-treatment (Kranzler et al., 2011, J Clin Psychopharmacol 31:22-30). We examined the main and interaction effects with time of 3 between-subject factors (medication group, age of onset of AD [late-onset alcoholics, LOAs, vs. early-onset alcoholics, EOAs], and the tri-allelic 5-HTTLPR genotype) on drinking days (DDs) and heavy drinking days (HDDs).
resultsThe medication group effect, which was significant during treatment, remained significant during the 3-month follow-up period for L'/L' LOAs, with the sertraline group having fewer DDs than the placebo group (p = 0.027). However, the medication group effect seen in L'/L' EOAs during treatment was no longer significant (p = 0.48). There were no significant effects in S' carriers at the 3-month follow-up visit, or in either genotype group at the 6-month follow-up.
conclusionsThe beneficial effects of sertraline observed in LOAs during treatment persisted during the 3-month post-treatment period. Additional studies are needed to validate these pharmacogenetic findings, which together with the effects seen during active treatment support the use of sertraline only in LOAs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.